Rescheduling
Rescheduling · page 6
- Uncategorized
Head Of US FDA Says ‘No Reason’ DEA Should Delay Cannabis Rescheduling
The head of the US Food and Drug Administration (FDA), Robert Califf, told elected officials this week that he believes there is ‘no reason for the DEA to delay’ making its decision on cannabis rescheduling.
- Uncategorized
80% Chance Rescheduling Decision Will Be Made In Coming Months, As DEA Raises Concerns
A decision from the US Drug Enforcement Agency (DEA) on cannabis rescheduling is 80% likely to come in the next few months, according to new analysis.
- Uncategorized
Cannabis Rescheduling ‘Would Fail To Deliver On President Biden’s Promises’ Of Reform, Say Advocacy Groups
Cannabis rescheduling would ‘continue the very criminalization that Biden said he would end’, according to leading US advocacy groups that have urged the government to go further.
- Uncategorized
‘Reject Any Argument’ Treaties Prevent Cannabis Rescheduling, Congresswoman Urges
Democratic Congresswoman Sydney Kamlager-Dove has become the latest high-profile voice to call on the US Drug Enforcement Administration (DEA) to reschedule cannabis.
- Uncategorized
Pressure Mounts on Biden Administration to Push Through Cannabis Rescheduling as Strategists Claim it Could be Election Winner
Numerous leading veterans groups and a group of prominent US law enforcement leaders have become the latest to throw their weight behind rescheduling cannabis.
- Uncategorized
FDA Unveils Details of Cannabis Rescheduling Research, Including Social Media Monitoring
The US Food and Drug Administration (FDA) has released a swathe of new details into the research it conducted into cannabis, ultimately leading it to recommend its rescheduling.
- Uncategorized
DEA Deadline to Respond to Democratic Senators on Rescheduling Missed, As Efforts to Clarify Timeline Continue
US Democratic Senators’ demands for the Drug Enforcement Agency (DEA) to make public the steps it is taking to act on the recommendations from the Department of Health and Human Services (HHS) that cannabis should be rescheduled.
- Uncategorized
US Cannabis Stock Prices up 25% Since Publication of Rescheduling Recommendation
US cannabis stock prices have rallied once again this week following the publication of the fully unredacted 252-page cannabis rescheduling recommendation.
- Opinion
US Cannabis Rescheduling Primed to Set Off a Global Cannabis Explosion
Written by Michael Sassano, CEO, Somai Pharmaceuticals On January 12, the United States Department of Health and Human Services (HHS) released a letter and supporting 252-page document that will make it extremely difficult for the Drug Enforcement Agency (DEA) to ignore its findings on the benefits of cannabis and all but ensuring that the U.S.
- Uncategorized
US Cannabis Stocks Spike as DEA Confirms Cannabis Reclassification Review
The US Drug Enforcement Administration (DEA) has confirmed that it is conducting a review into the reclassification of cannabis, but has asserted its ‘final authority’ over the decision.
